ChemLifeIntel/Companies/TG Therapeutics, Inc.

TG Therapeutics, Inc.

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 1 of 1 briefs on TG Therapeutics, Inc.

CLINICAL & PIPELINE·Clinical Trial Termination

TG Therapeutics Halts Phase 1b Trial for Novel CD47/CD19 Bispecific TG-1801 in B-Cell Lymphoma and CLL

TG Therapeutics, Inc. has terminated its Phase 1b clinical trial (NCT04806035) for TG-1801, a novel CD47/CD19 bispecific antibody, citing a "Strategic/Business Decision." This impacts the oncology pipeline, halting development for B-cell lymphomas and CLL. Procurement and regulatory teams must reassess future supply chain needs and market opportunities in this therapeutic area.

90-Day Activity

TG Therapeutics,HSN 3002.15

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

4h ago Clinical Trial Termination